Loading...
Market
Story
Japan's PHDP5 Peptide Reverses Alzheimer’s Symptoms in Mice
Jun 24, 2024, 02:01 PM
Researchers at the Okinawa Institute of Science and Technology (OIST) in Japan have developed a synthetic peptide, PHDP5, that successfully reversed Alzheimer’s symptoms in mice. The peptide targets and improves brain synaptic function, effectively restoring cognitive function and memory by reversing synapse damage. Treated mice exhibited the same cognitive function as healthy mice, highlighting the potential of PHDP5 to cross the blood-brain barrier and offer a new therapeutic approach for Alzheimer’s disease.
View original story
Similar markets
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Novo Nordisk • 25%
Sanofi • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Stock price increases by more than 10% • 25%
Stock price increases by less than 10% • 25%
Stock price remains stable • 25%
Stock price decreases • 25%